Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at ValuEngine

Moleculin Biotech (NASDAQ:MBRX) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.

Separately, Roth Capital reiterated a “buy” rating on shares of Moleculin Biotech in a research report on Thursday, May 23rd.

MBRX stock remained flat at $$1.06 during midday trading on Thursday. 238,284 shares of the company’s stock were exchanged, compared to its average volume of 358,159. Moleculin Biotech has a 12 month low of $0.78 and a 12 month high of $3.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.49 and a quick ratio of 1.49. The company has a market cap of $49.26 million, a PE ratio of -2.08 and a beta of 2.03. The company’s 50-day simple moving average is $1.20.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Monday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). As a group, sell-side analysts predict that Moleculin Biotech will post -0.37 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in MBRX. BB&T Corp increased its stake in shares of Moleculin Biotech by 55.6% during the 1st quarter. BB&T Corp now owns 140,000 shares of the company’s stock worth $113,000 after purchasing an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Moleculin Biotech during the 4th quarter worth $36,000. Taylor Cottrill Erickson & Associates Inc. increased its stake in shares of Moleculin Biotech by 24.6% during the 1st quarter. Taylor Cottrill Erickson & Associates Inc. now owns 151,781 shares of the company’s stock worth $123,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Moleculin Biotech by 109.1% during the 4th quarter. Northern Trust Corp now owns 47,918 shares of the company’s stock worth $50,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 4.84% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Featured Article: What is a Real Estate Investment Trust (REIT)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.